Literature DB >> 8149615

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

S M Marcovina1, J J Albers, H Kennedy, J V Mei, L O Henderson, W H Hannon.   

Abstract

We performed temporal and thermal stability studies on SP3-07, a liquid-stabilized reference material for apolipoprotein (apo) B, selected during the previous phase of the International Federation of Clinical Chemistry project on standardization of apolipoprotein measurements. Results indicate that SP3-07 stored at -70 degrees C has the long-term stability required for a reference material. We assigned an accuracy-based apo B value of 1.22 g/L to SP3-07, using a nephelometric method that was calibrated with freshly isolated low-density lipoprotein for which the apo B mass value was determined by a standardized sodium dodecyl sulfate-Lowry procedure. Using a common protocol, the study participants transferred the assigned mass value from SP3-07 to the individual calibrators of the analytical systems and measured the apo B concentration of 20 fresh-frozen samples obtained from individual donors and covering a clinically relevant range of apo B values. The among-laboratory CV on these samples, analyzed by 25 analytical systems, ranged from 3.1% to 6.7%. These results demonstrate the lack of matrix effects of SP3-07 and its ability to provide accurate and comparable apo B values in a variety of immunochemical methods. On the basis of the outcome of these studies, the World Health Organization has endorsed SP3-07 as the International Reference Material for Apolipoprotein B.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149615

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  38 in total

1.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

Review 2.  ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.

Authors:  A F Winder; W Richmond; D T Vallance
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative.

Authors:  Seth S Martin; Arif A Khokhar; Heidi T May; Krishnaji R Kulkarni; Michael J Blaha; Parag H Joshi; Peter P Toth; Joseph B Muhlestein; Jeffrey L Anderson; Stacey Knight; Yan Li; John A Spertus; Steven R Jones
Journal:  Eur Heart J       Date:  2014-06-30       Impact factor: 29.983

4.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.

Authors:  M Cnop; P J Havel; K M Utzschneider; D B Carr; M K Sinha; E J Boyko; B M Retzlaff; R H Knopp; J D Brunzell; S E Kahn
Journal:  Diabetologia       Date:  2003-04-10       Impact factor: 10.122

5.  Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients.

Authors:  Parsuram Nayak; Suchismita Panda; Pravat Kumar Thatoi; Roma Rattan; Srikrushna Mohapatra; Pramila Kumari Mishra
Journal:  J Clin Diagn Res       Date:  2016-10-01

6.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

Authors:  S D Sibley; J E Hokanson; M W Steffes; J Q Purnell; S M Marcovina; P A Cleary; J D Brunzell
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

7.  Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study.

Authors:  Carlos Lorenzo; Sara Hartnett; Anthony J Hanley; Marian J Rewers; Lynne E Wagenknecht; Andrew J Karter; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

8.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

9.  Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites.

Authors:  Seth S Martin; Atif N Qasim; Nehal N Mehta; Megan Wolfe; Karen Terembula; Stanley Schwartz; Nayyar Iqbal; Mark Schutta; Roshanak Bagheri; Muredach P Reilly
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

10.  The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

Authors:  Sarah Parish; Richard Peto; Alison Palmer; Robert Clarke; Sarah Lewington; Alison Offer; Gary Whitlock; Sarah Clark; Linda Youngman; Peter Sleight; Rory Collins
Journal:  Eur Heart J       Date:  2009-06-11       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.